This post has been archived and contains information that may be out of date.
Walter Ginter began using heroin in the early 1970s while serving in the Army. By 1977, desperate to kick the habit, he turned to daily doses of methadone, a synthetic opioid that eases withdrawal and decreases cravings. The treatment worked.
“I have a good life today,” says Ginter, 69, project director for the New York-based Medication Assisted Recovery Support Project. “I wouldn’t have it without medication.”
Ginter was a member of a National Academies of Sciences, Engineering and Medicine committee that examined the three medications — methadone, buprenorphine (typically sold under the Suboxone brand name) and extended-release naltrexone (Vivitrol) — that the government has approved to treat opioid addiction.
